Sophia El Hamichi, MD
Retina Specialist · Fort Myers, FLNPI 1255098562
Payments from drug & device makers
Across 42 payments — averaging $34.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$343
- Regeneron Healthcare Solutions, Inc.$286
- Biotissue Holdings Inc.$149
- Eyevance Pharmaceuticals LLC$144
- Harrow Eye, LLC$115
- Genentech USA, Inc.$107
- plus $314 from 8 others
Across 348 payments — averaging $39.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Notal Vision, Inc.$14K
What the payments were for
- Food & beverage$1,458100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 13 | $343 |
| Regeneron Healthcare Solutions, Inc. | 7 | $286 |
| Biotissue Holdings Inc. | 1 | $149 |
| Eyevance Pharmaceuticals LLC | 1 | $144 |
| Harrow Eye, LLC | 4 | $115 |
| Genentech USA, Inc. | 4 | $107 |
| Notal Vision, Inc. | 3 | $82 |
| Alcon | 1 | $58 |
| Astellas Pharma US Inc | 2 | $51 |
| Ocular Therapeutix, Inc. | 2 | $39 |
| Apellis Pharmaceuticals, Inc. | 1 | $25 |
| ANI Pharmaceuticals, Inc. | 1 | $23 |
| Alimera Sciences, Inc. | 1 | $22 |
| Bausch & Lomb Americas Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,458 in reported general payments places this provider in the 30th percentile of 118 retina specialist providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 61 | $2,926 |
| Ketorolac Tromethamine | 17 | $783 |
| MoxifloxacinMoxifloxacin Hcl | 11 | $399 |
| Brimonidine Tartrate | 28 | $262 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 16 | $240 |
| Ofloxacin | 18 | $230 |
| Latanoprost | 29 | $230 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Fort Myers
- Ashish SharmaFort Myers$994K
- Katrina MearsFort Myers$431K
- Alexander EatonFort Myers$210K
- Shailesh GuptaDeerfield Beach$18.8M
- Vrinda HershbergerMelbourne$8.2M
- Sunil GuptaPensacola$8.1M
- Stuart BurgessPlantation$4.6M
- Eduardo UchiyamaFt Lauderdale$4.1M
- Drew BawcombeDeerfield Beach$2M
- Dana DeupreeSpring Hill$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.